On one hand, exosomes have emerged as suitable nanoplatforms for therapeutic compounds delivery to cells; On the other hand, cell membrane-derived nanovesicles are biomimetic liposomes derived from source cell membranes via extrusion process and can coat nanoparticle cores or used isolated. Once both have origin on cell membranes, can we expect differences on the suitability of each type of nanosystem?

More Miguel Pereira-Silva's questions See All
Similar questions and discussions